Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284231 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
A Phase 1 study of Gastrointestinal Adenocarcinomas, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 4
- Study locations
NCT01284231 is a Phase 1 study of Gastrointestinal Adenocarcinomas that has completed, run by MedImmune. The registered enrollment target is 78 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT01284231, a Phase 1 study of Gastrointestinal Adenocarcinomas, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 4
- Study locations
Study Summary
To determine the maximum tolerated dose and/or optimum biologic dose of MEDI-565 in adult subjects and evaluate the safety profile in adult subjects with advanced gastrointestinal adenocarcinomas who have no available standard or curative treatments.
Conditions Studied
Interventions
- DRUG MEDI-565
Study Locations (4)
District of Columbia
- Research Site - Washington D.C.
Georgia
- Research Site - Augusta
North Carolina
- Research Site - Durham
Pennsylvania
- Research Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284231
The ClinicalTrials.gov registry entry for NCT01284231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Adenocarcinomas appearing as the primary indexed condition, and to 1 intervention - of which MEDI-565 is the first listed.
NCT01284231 reports 4 study locations spanning 4 distinct geographic areas - top geographies include District of Columbia, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01284231 about?
NCT01284231 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas". To determine the maximum tolerated dose and/or optimum biologic dose of MEDI-565 in adult subjects and evaluate the safety profile in adult subjects with advanced gastrointestinal adenocarcinomas who have no available standard or curative treatments.
What is the current status of trial NCT01284231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2010-12. Estimated completion is 2015-01.
What conditions does trial NCT01284231 study?
This clinical trial studies the following conditions: Gastrointestinal Adenocarcinomas.
What interventions are being tested in trial NCT01284231?
The interventions under investigation include: MEDI-565 (DRUG).
Who is sponsoring clinical trial NCT01284231?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01284231 being conducted?
This trial has 4 study locations across District of Columbia, Georgia, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.